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ANTITHYROID DRUGS OR RADIOIODINE AS 
FIRST-LINE THERAPY OF GRAVES’ 
HYPERTHYROIDISM IN A COUNTRY WITH 
STRICT REGULATIONS FOR RADIATION 
PROTECTION?
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OBJECTIVES: Radioiodine therapy has become more
economic in Germany since the new recommendations by
the Federal German Radiation Protection Committee for
patient discharge.
METHODS: Costing models for primary conservative or
primary radioiodine therapy of Graves’ hyperthyroidism
included the overall costs from first diagnosis to regular
follow-up care over 30 years. The costs of hospitalization
for radioiodine therapy were calculated for 300 patients,
discharged with 250 MBq I-131 residual activity. Sensi-
tivity analyses took into account the relapse rate of con-
servative or radioiodine therapy, use of diagnostic tests,
level of health insurance, drops in productivity, and a dis-
count factor.
RESULTS: Cost estimates based on life expectancy
ranged from 6682 DM to 41,216 DM for primary con-
servative treatment and from 7811 DM to 35,430 DM
for radioiodine therapy in Germany, depending on the
costing model used. The maximum cost savings amounted
to 1129 DM for conservative treatment and 5786 DM
for radioiodine therapy. Antithyroid drugs were consid-
ered cost-effective when they achieved relapse rates of
50% or less, a cut in the number of tests needed and re-
duced working hours. Failure to meet any one of these
conditions makes radioiodine therapy most cost-effective
in spite of hospitalization (mean 4.6 days). If the patient
received long-term antithryoid drugs for repeated re-
lapses, the costs can run to 7849 DM more than radioio-
dine therapy.
CONCLUSIONS: Radioiodine is a cost-effective, first-
line therapy in patients with a special risk of relapse after
primary conservative therapy (goiter, younger patient,
persistent elevated TSH receptor antibodies or Tc-up-
take) even in a country with strict regulations for radia-
tion protection.
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OBJECTIVE: Foot ulcers are a common complication of
diabetes and are estimated to affect 15% of patients with
diabetes during their lifetime. Lower extremity ulcer care
represents a significant proportion of the cost of diabetes;
around 25% of the cost of inpatient care for these pa-
tients is estimated to be due to foot ulcers, primarily due
to infections and amputations. To examine the relative
burden of foot ulcers over and above diabetes alone, this
study utilized a comprehensive measurement strategy. 
METHODS: First, patient interviews and focus group
discussions aided in the development of a quality of life
assessment tool, the Diabetic Foot Ulcer Scale (DFS).
RESULTS: Foot ulcer patients reported that loss of mobil-
ity caused by the non-weight-bearing treatment regimens
placed many restrictions on their daily activities, leisure
pursuits and social interactions, resulting in a substantial
amount of frustration and anger. The uncertainty of
whether lower extremity ulcers will ever heal or will result
in amputation is also a source of worry to patients. Pa-
tients also often feel isolated and a burden to others. Thus,
the interviews yielded 11 domains which were found to be
impacted by foot ulcers: Leisure, Physical Health, Daily
Activities, Emotions, Non-compliance, Family, Friends,
Treatment, Satisfaction, Positive Attitude, and Financial.
The 58 item DFS was developed and assessed for its face
and content validity by patients and clinicians. Finally, the
DFS was administered to 173 patients with diabetes to as-
sess the psychometric properties of the DFS. The DFS met
or exceeded the minimum standard criteria for reliability,
construct validity and clinical validity. 
CONCLUSIONS: The wider application of the DFS in
foot ulcer management will provide clinicians with useful
information on the total burden of lower extremity ulcers
on patients, as well as giving them specific areas to target
with support and counseling. The impact of different treat-
ment regimens can also be compared from the patient’s
perspective, thus allowing more efficient decisions on the
design and application of different treatment strategies.
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OBJECTIVE: This study assessed the feasibility of the
contingent valuation method for measuring the monetary
value to patients of avoiding allogeneic transfusions dur-
ing orthopedic surgery.
METHODS: A survey was administered to 400 patients
randomized to receiving Epoetin- preoperatively or un-
dergoing autologous blood donation (ABD) in a US trial
in 1996/97. The survey was administered after patients
received Epoetin- or underwent ABD. The chance of
avoiding allogeneic transfusion was stated as 85% and
75% in the Epoetin- and ABD groups, respectively. Par-
ticipants were asked whether they would pay a particular
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price out of their own pocket in order to obtain treatment
with Epoetin- rather than undergo ABD. One of six
prices was randomly assigned to each participant ($100,
500, 1000, 1500, 2000, 2500). Internal consistency was
examined by correlating willingness to pay (WTP) values
with risk perceptions and patient characteristics.
RESULTS: Mean WTP for Epoetin- was $1845 in the
Epoetin- group and $1309 per patient in the ABD
group. In multivariate analysis, WTP varied with fear of
transfusion and education level, as expected. The proba-
bility of purchasing Epoetin- continuously decreased
with price in 10 of 12 observations. 
CONCLUSIONS: Our findings indicate high internal con-
sistency of the survey. Patients indicated considerable WTP
for Epoetin- to reduce the risk of allogeneic transfusion
relative to ABD. As indicated by the higher willingness to
pay in the Epoetin- group, patients may perceive autolo-
gous blood donation to be more inconvenient than they
rate it once they have experienced the procedure.
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OBJECTIVES: A US multicenter study of Epoetin- ver-
sus pre-operative autologous donation (PAD) in patients
undergoing major orthopedic surgery showed that Epoe-
tin- reduced the risk of allogeneic transfusion. In addi-
tion, patients receiving Epoetin- had higher postopera-
tive hemoglobin levels than PAD patients. We examined
1) whether higher postoperative hemoglobin levels are as-
sociated with a reduced postoperative length of stay; and
2) the relationship between treatment assignment and
postoperative stay.
METHODS: Analyses were stratified by type of surgery
(hip or knee). Multivariate analysis was used to explore
the relationship between postoperative hemoglobin levels
and postoperative length of stay. The relation between
treatment assignment and postoperative stay was exam-
ined using both univariate and multivariate analysis.
RESULTS: We found a relationship between postopera-
tive hemoglobin levels and postoperative length of stay in
the patients undergoing knee replacement, but not among
hip patients. In the univariate analysis, there was no dif-
ference in postoperative stay between the Epoetin- group
and the PAD group among hip patients 4.91 (2.07 days)
versus 4.90 (2.66 days). Among knee patients, the post-
operative length of stay in the Epoetin- group was 4.27
(1.60 days, significantly lower than in the PAD group,
4.70 (1.80 days [p  .044]). Multivariate analysis con-
firmed these findings. 
CONCLUSIONS: In addition to reducing the exposure to
allogeneic blood, Epoetin- significantly reduced post-
operative length of stay when compared to pre-operative
autologous donation among patients undergoing knee re-
placement surgery. The absence of a similar effect among
patients undergoing hip replacement may be explained by
the finding that postoperative hemoglobin level is not a
predictor of postoperative length of stay among these pa-
tients.
